STOCKS TELEGRAPH

Tag: MESO

  • Pre-Market Cues: 28 Stocks Roaring for Change On December 18th

    Pre-Market Cues: 28 Stocks Roaring for Change On December 18th

    Seneca Biopharma Inc. (SNCA), a Biotechnology company, rose about 0.2% at $0.96 in pre-market trading Friday after declaring merger agreement with Leading BioSciences, Inc. under which a wholly owned subsidiary of Seneca will merge with LBS in an all-stock transaction.

    Palantir Technologies Inc. (PLTR) lost over -3.97% at $26.15 in pre-market trading Friday December 18, 2020 after reporting that it will hold its inaugural “Live Demo Day” on Tuesday, January 26, 2021 at 4:30pm ET.

    Atossa Therapeutics Inc. (ATOS) stock plunged -0.02% to $0.86 in the pre-market trading following its declaration of pricing of $14.0 million registered direct offering priced at-the-market. The most recent rating by Maxim Group, on January 26, 2018, is a Buy.

    Virgin Galactic Holdings Inc. (NYSE: SPCE) shares are trading down -6.27% at $23.9 at the time of writing. The company recently revealed an update following its test flight on December 12, 2020. Company’s 52-week ranged between $9.06 to $42.49. Analysts have a consensus price target of $19.

    BlackBerry Limited (BB), a Software – Infrastructure company, dropped about -4.36% at $7.9 in pre-market trading Friday after releasing its financial results for the three months ended November 30, 2020

    Before the trading started on December 18, 2020, Uxin Limited (UXIN) is up 4.5% to reach $1.16 following its announcement of unaudited financial results for the quarter ended September 30, 2020. It has been trading in a 52-week range of $0.72 to $3.07.

    Coeur Mining Inc. (CDE) stock plunged -2.98% to $10.76 in the pre-market trading. The firm recently revealed details of the expansion of its Rochester silver-gold mine in Nevada, reflecting significant reserve growth and the benefits of a larger-scale expansion project. The most recent rating by Noble Capital Markets, on September 14, 2020, is an Outperform.

    Novan Inc. (NASDAQ: NOVN) shares are trading up 6.25% at $0.68 at the time of writing. The company lately reported that it has enrolled 525 patients of the approximately 850 patients expected to enroll in the B-SIMPLE4 pivotal Phase 3 clinical study of SB206. Company’s 52-week ranged between $0.22 to $3.72.

    CNS Pharmaceuticals Inc. (CNSP), a Biotechnology company, rose about 15.2% at $2.88 in pre-market trading Friday after announcing FDA approval of IND application for its brain cancer drug candidate Berubicin.

    United States Steel Corporation (X) stock moved down -4.26 percent to $17.77 in the pre-market trading after reporting that fourth quarter 2020 adjusted EBITDA is expected to be approximately $55 million and expected fourth quarter 2020 adjusted diluted loss per share to be approximately ($0.85).

    BioCardia Inc. (BCDA) lost over -6.09% at $4.01 in pre-market trading Friday December 18, 2020 following an announcement from the firm that the independent Data Safety Monitoring Board (DSMB) has completed its prespecified data review for the Phase III pivotal CardiAMP Heart Failure Trial.

    Before the trading started on December 18, 2020, Ampio Pharmaceuticals Inc. (AMPE) is up 8.43% to reach $1.93 after revealing the completion of its Phase I clinical trial and initiation of the first steps for a global Phase II clinical trial for intravenous (“IV”) Ampion treatment in COVID-19 patients. It has been trading in a 52-week range of $0.31 to $1.69.

    Drive Shack Inc. (NYSE: DS) shares are trading up 5.47% at $3.47 at the time of writing following the opening of its 65,000-square-foot entertainment golf venue located in Orlando. Company’s 52-week ranged between $0.86 to $4.19. Analysts have a consensus price target of $4.

    IZEA Worldwide Inc. (IZEA) tumbled over -3.7% at $1.04 in pre-market trading today. The company recently reported that it has just been awarded a mid-six figure contract from a Fortune 500 Manufacturer.

    Exela Technologies Inc. (XELA), a Software – Application company, rose about 81.87% at $0.66 in pre-market trading Friday after declaring that it has entered into a 5-year, $145 million term loan facility with Angelo Gordon, a global alternative investment firm.

    FedEx Corporation (FDX) stock moved down -2.89 percent to $283.8 in the pre-market trading after declaring strong results for the quarter ended November 30.

    Guardion Health Sciences Inc. (GHSI) stock plunged -2.13% to $0.23 in the pre-market trading. The firm recently declared progress on the introduction of its new vision support/energy drink, Epiq-V, which is under development for the United States and international markets.

    Amyris Inc. (NASDAQ: AMRS) shares are trading up 3.68% at $4.23 at the time of writing. Company’s 52-week ranged between $1.40 to $6.07. Analysts have a consensus price target of $3.35.

    Mereo BioPharma Group plc (MREO), a Biotechnology company, rose about 40.27% at $3.1 in pre-market trading Friday following the declaration of a license and collaboration agreement with Ultragenyx Pharmaceutical Inc. (RARE), for setrusumab, a monoclonal antibody in clinical development for osteogenesis imperfecta (OI).

    Surface Oncology Inc. (SURF) gained over 17.51% at $10.0 in pre-market trading Friday December 18, 2020 after revealing exclusive license agreement with GSK for novel immunotherapy program.

    Neovasc Inc. (NVCN) is down more than -8.52% at $0.91 in pre-market hours Friday December 18, 2020 after reporting the publication of peer-reviewed article in EuroIntervention. The stock had jumped over 3.61% to $0.99 in the last trading session.

    BioLineRx Ltd. (BLRX) tumbled over -1.1% at $2.7 in pre-market trading today. The firm lately declared final results from Phase 2a COMBAT/KEYNOTE-202 triple combination study of Motixafortide in second line Metastatic Pancreatic Cancer (PDAC).

    VYNE Therapeutics Inc. (VYNE), a Biotechnology company, rose about 8.05% at $1.88 in pre-market trading Friday after declaring the successful completion of its End-of-Phase 2 Meeting with the U.S. Food and Drug Administration (FDA).

    Before the trading started on December 18, 2020, Mesoblast Limited (MESO) is down -26.75% to reach $9.94 after announcing an update on COVID-19 ARDS trial. It has been trading in a 52-week range of $3.12 to $21.28.

    Applied DNA Sciences Inc. (APDN) stock plunged -12.02% to $5.49 in the pre-market trading after reporting consolidated financial results for the full fiscal year and quarter ended September 30, 2020. The most recent rating by H.C. Wainwright, on July 20, 2020, is a Buy.

    Conformis Inc. (NASDAQ: CFMS) shares are trading up 3.8% at $0.6693 at the time of writing. The firm lately revealed the U.S. commercial launch of the Company’s new Cordera™ Match Hip System. Company’s 52-week ranged between $0.50 to $1.66.

    Auris Medical Holding Ltd. (EARS) grew over 1.5% at $2.7 in pre-market trading today. The company recently provided a business update related to the Company’s funding position, its AM-301 program for the protection against airborne pathogens and allergens and the ongoing strategy review process.

    Sonoma Pharmaceuticals Inc. (SNOA) stock moved up 19.79 percent to $9.14 in the pre-market trading following the announcement of partnership with Gabriel Science, LLC for dental.

  • Mesobllast ltd. (NASDAQ: MESO) bursting in the after-market session

    Mesobllast ltd. (NASDAQ: MESO) bursting in the after-market session

    Mesobllast ltd. (MESO) the stock was flying as high as 10.12% in the post-market session on December 1, 2020, even after it was reported that Frank R. Cruz’s Law Office advises clients that class action cases have been brought on behalf of the owners of the following publicly listed firms. Investors have until the time limits set out below to file a lawsuit with the lead plaintiff.

    Investors experiencing damages in their assets are urged to contact the Frank R. Cruz Law Office to discuss their civil interests in these class cases at 310-914-5007 or via e-mail fcruz@frankcruzlaw.com.

    Mesobllast Minimal (NASDAQ: MESO)

    Class Period: April 16, 2019 – October 1, 2020.

    Lead Plaintiff Deadline: December 7, 2020

    The lawsuit alleges that during the Class Period, the Defenders made materially inaccurate and misleading claims and refused to reveal significant adverse information regarding the Company’s market, activities and prospects. Specifically, the Defenders refused to report to investors:

    (1) that the comparative review between the Phase 3 trial of Mesoblast and the three historical trials did not confirm the efficacy of remestemcel-L in steroid refractory aGVHD due to variations in nature between the four studies;

    (2) that as a result, the FDA was fairly likely to require more clinical studies;

    (3) that as a result, the commercialization of remestemcel-L in the U.S. was likely to be delayed; and (4) that as a result of the above, the optimistic comments of the Defenders on the Company’s market, operations, and prospects were materially deceptive and/or lack of a fair basis.

  • Top Performers Braving the Mixed Market Sentiment

    Top Performers Braving the Mixed Market Sentiment

    It’s a mixed afternoon in the stock markets after retail data missed estimates. The consensus was that the retail sales would rise by 2.1% in July, but the numbers came back at 1.2%. This shows that the economy is still weak and may be in need of another bailout. However, there is optimism that the numbers also point to resilience given that money from the previous bailout is already spent. Economists believe that the numbers could point to recovery and that August could post even better numbers.  Despite the optimism, there are concerns that the market could be hurt by the fact that Congress is going into recess without a deal on the bailout. Failure to clinch a deal creates additional risks to the economy. In this environment of mixed sentiment, there are stocks that are outperforming the market. Some of the top performers this afternoon are:

    Sky Solar Holdings Ltd [NASDAQ: SKYS]

    Sky Solar Holdings Ltd is a top performer this afternoon and is up by 37.42%. This follows the company’s announcement of a Cayman Court Decision that was entered on the 30th of July, 2020.  The company also announced that yesterday, it had filed a complaint against Hudson Solar Cayman in the supreme court of New York. The company’s lawsuit wants a declaratory judgment on some of the aspects of the allegations by Hudson. The massive jump in value shows that investors are happy with the events that have transpired so far.

    Mesoblast Limited [NASDAQ: MESO]

    This is another big gainer this afternoon and is up by 46%. The stock’s rally follows news that the US FDA committee had voted 9:1 in support of Remestemcel-L in children that are suffering from Steroid Refractory Acute Graft Versus Host.  The company’s CEO, Dr. Fred Grossman stated that the treatment of Steroid-Refractory Acute Graft Versus Host was of utmost importance especially in kids below the age of 12. He added that the company was happy with the latest developments and that it was committed to an even closer working relationship with the FDA, as they review the treatment.  According to Dr. Joanne Kurtzberg, a professional of pediatrics at the Duke University Medical Center, the disease currently has no FDA-approved treatments.

    Muscle Maker Inc. [NASDAQ: GRIL]

    Muscle Maker Inc.is gaining this afternoon and is currently up by 15%. This follows the company’s announcement that it had started construction at four locations.  The construction will happen at 4 college locations namely: Manassas, Alexandria, Woodbridge, and Loudoun, all within the Northern Virginia Community College. The company also stated that it would give students a grab-and-go option.